NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
NeoGenomics, Inc. (NASDAQ: NEO) announced the launch of new genomic tests, including Neo Comprehensive - Solid Tumor and Neo Comprehensive - Myeloid Disorders. These tests enhance their next-generation sequencing (NGS) portfolio, aiming to improve patient care through comprehensive genomic profiling.
The Solid Tumor test analyzes 517 genes, while the Myeloid test focuses on 164 genes related to myeloid neoplasms. Improvements include faster turnaround times and streamlined reporting. Additionally, software tools NeoAccess™ and NeoSeek™ support clinicians in decision-making and patient management.
- Launch of Neo Comprehensive - Solid Tumor and Neo Comprehensive - Myeloid Disorders tests.
- Improvements in test turnaround times and reporting formats.
- Enhanced testing capabilities with the largest panels available in their segments.
- None.
FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the expansion of their next-generation sequencing (NGS) portfolio of innovative products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile (CGP) for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms.
"We are committed to offering a broad spectrum of next-generation tests paired with unparalleled service to enhance patient care," said Chris Smith, CEO of NeoGenomics. "With our new, easy to interpret reports, even faster turn-around times, and low sample requirements, these new tests offer clinicians industry leading testing options to support the management of their patients with cancer, across various stages and types of disease."
Neo Comprehensive - Solid Tumor is NeoGenomics' largest solid tumor, pan cancer assay available to date. This CGP detects genomic alterations that are most relevant in diagnosis, therapy selection, prognosis and clinical trials. The panel includes 517 genes by both DNA and RNA NGS, microsatellite instability (MSI), and tumor mutational burden (TMB). With this test comes an improved turnaround time and a streamlined test report format.
Neo Comprehensive - Myeloid Disorders is available as an enhancement of NeoGenomics' previous Myeloid panel, making it the largest DNA and RNA NGS myeloid panel on the market with the most clinically actionable features, including single nucleotide variants (SNV), copy number variants (CNV), insertions and deletions (InDel), and fusions.
In parallel with the two product launches, NeoGenomics is also introducing two software resources to complement their testing menu: NeoAccess™, a test requisitioning tool which includes clinical decision support, up-front patient benefits check and prior authorization assistance abilities; and NeoSeek™, a platform that allows clinicians the ability to mine their previous testing data to identify their patients who may be biomarker eligible for a new therapy or clinical trial.
About Neo Comprehensive - Solid Tumor
Neo Comprehensive - Solid Tumor is a solid tumor comprehensive genomic profile (CGP) totaling 517 genes capturing: CNVs, SNVs, InDels, fusions, splice variants, TMB and MSI by both DNA and RNA NGS methods. In addition, this CGP offers an easy to interpret report format, improved test turn-around time and decreased specimen requirements.
About Neo Comprehensive - Myeloid Disorders
Neo Comprehensive - Myeloid Disorders is a comprehensive genomic profile (CGP) analyzing 164 genes relevant to the assessment of myeloid neoplasms, detecting SNVs, InDels, CNVs, and fusions utilizing DNA and RNA NGS methods. It is aligned with the latest guidelines and the WHO 5th Edition Classification, covering a wide spectrum of myeloid disorders, including acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), myeloproliferative neoplasms (MPN), myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement, mastocytosis, histiocytic neoplasms, and more.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK, Rolle, Switzerland, and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," expect," plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project, "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 23, 2023 as well as other information previously filed with the SEC.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
For further information, please contact:
NeoGenomics, Inc.
Vishal Sikri
President, Advanced Diagnostics
Vishal.Sikri@neogenomics.com
T: +1-847-840-3702
Kendra Sweeney
Vice President, Investor Relations and Communications
Kendra.Sweeney@neogenomics.com
T: +1-239-877-7474
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/743202/NeoGenomics-Expands-NGS-Portfolio-with-Launch-of-Neo-ComprehensiveTM--Solid-Tumor-CGP-and-Neo-ComprehensiveTM--Myeloid-Disorders-CGP
FAQ
What new products did NeoGenomics announce on March 13, 2023?
What is the significance of the Neo Comprehensive - Solid Tumor test?
How does the Neo Comprehensive - Myeloid Disorders test improve upon previous offerings?
What software tools were introduced alongside the new tests by NeoGenomics?
What are the main benefits of NeoGenomics' new tests?
